Educational content on VJHemOnc is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

The Lymphoma Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), BMS (Gold), Johnson & Johnson (Gold), Takeda (Silver) and Galapagos (Bronze). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.

Share this video  

EORTC CLTF 2018 | Future antibody avenues for cutaneous lymphoma treatment

Pietro Quaglino • 27 Sep 2018
EORTC CLTF 2018
Cutaneous T-Cell Lymphoma Lymphoma Non-Hodgkin Lymphoma Rare Diseases T-Cell Lymphoma Antibodies Brentuximab vedotin Checkpoint inhibitors Mogamulizumab

Speaking from the European Organisation for the Research and Treatment of Cancer (EORTC) Cutaneous Lymphoma Task Force (CLTF) 2018 Congress, held in St. Gallen, Switzerland, Pietro Quaglino, MD, of the University of Turin, Turin, Italy, gives his insight into the novel therapies being explored for cutaneous T-cell lymphomas, including bretuximab vedotin and mogamulizumab .

More from Pietro Quaglino

Clinical scoring system for Sézary syndrome: results from a retrospective study 2:25
Clinical scoring system for Sézary syndrome: results from a retrospective study
Pietro Quaglino • 1 Oct 2018
Current treatment landscape & unmet needs in cutaneous T-cell lymphoma: quality of life 1:29
Current treatment landscape & unmet needs in cutaneous T-cell lymphoma: quality of life
Pietro Quaglino • 28 Sep 2018

Related Videos

Long-term follow-up results from ELM-2: odronextamab in R/R FL 8:08
Long-term follow-up results from ELM-2: odronextamab in R/R FL
Gottfried von Keudell • 18 Sep 2025
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL 1:24
The efficacy of glofitamab in patients with heavily pre-treated R/R MCL
Tycel Phillips • 5 Sep 2025
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute 1:01
Bringing clinical trials to the community: current approaches at Sarah Cannon Research Institute
Krish Patel • 4 Sep 2025
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations 1:52
Bispecifics and CAR T-cell therapy in lymphoma: sequencing strategies and considerations
Tycel Phillips • 5 Sep 2025
The content of VJHemOnc is intended for healthcare professionals